Clinical Trials
2 trialsNCT06964737 2026-05-08
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03598244 2025-04-20
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting